Gene expression patterns associated with neurological disease in human HIV infection

Pietro Paolo Sanna¹*, Vez Repunte-Canonigo¹, Eliezer Masliah²*, Celine Lefebvre¹,³

¹ Department of Immunology and Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, California, United States of America, ² Department of Neuroscience, University of California at San Diego, La Jolla, California, United States of America, ³ INSERM Unit U981, Gustave Roussy Institute, Villejuif, France

* Current address: National Institute on Aging, National Institutes of Health, Bethesda, Maryland, United States of America
* psanna@scripps.edu

Abstract

The pathogenesis and nosology of HIV-associated neurological disease (HAND) remain incompletely understood. Here, to provide new insight into the molecular events leading to neurocognitive impairments (NCI) in HIV infection, we analyzed pathway dysregulations in gene expression profiles of HIV-infected patients with or without NCI and HIV encephalitis (HIVE) and control subjects. The Gene Set Enrichment Analysis (GSEA) algorithm was used for pathway analyses in conjunction with the Molecular Signatures Database collection of canonical pathways (MSigDb). We analyzed pathway dysregulations in gene expression profiles of patients from the National NeuroAIDS Tissue Consortium (NNTC), which consists of samples from 3 different brain regions, including white matter, basal ganglia and frontal cortex of HIV-infected and control patients. While HIVE is characterized by widespread, uncontrolled inflammation and tissue damage, substantial gene expression evidence of induction of interferon (IFN), cytokines and tissue injury is apparent in all brain regions studied, even in the absence of NCI. Various degrees of white matter changes were present in all HIV-infected subjects and were the primary manifestation in patients with NCI in the absence of HIVE. In particular, NCI in patients without HIVE in the NNTC sample is associated with white matter expression of chemokines, cytokines and β-defensins, without significant activation of IFN. Altogether, the results identified distinct pathways differentially regulated over the course of neurological disease in HIV infection and provide a new perspective on the dynamics of pathogenic processes in the course of HIV neurological disease in humans. These results also demonstrate the power of the systems biology analyses and indicate that the establishment of larger human gene expression profile datasets will have the potential to provide novel mechanistic insight into the pathogenesis of neurological disease in HIV infection and identify better therapeutic targets for NCI.
Introduction
While the prevalence of severe HIV-associated dementia (HAD) has decreased since the introduction of combination antiretroviral therapy (cART), milder and chronic forms of neurocognitive impairment (NCI) including asymptomatic neurocognitive impairment (ANI) and HIV-associated neurocognitive disorders (HAND) as well as HIV-associated major depressive disorder remain high [1–7]. HIV encephalitis (HIVE) is considered to be the main neuropathological substrate of HAD [8–10]. NCI in the setting of cART is associated with synaptodendritic degeneration [7, 11, 12]. While the brain represents a sanctuary where HIV can persist due to suboptimal penetration of antiretroviral drugs [13], various studies highlighted the occurrence of NCI even in the setting of viral suppression [14, 15]. Chronic neuroinflammation is believed to drive neurodegeneration in cART-era HAND [7, 9, 16, 17]. However, the pathogenic mechanisms behind HAND remain unclear.

To identify gene expression correlates of neurological disease progression in HIV, we analyzed pathway dysregulations in brain regions of patients in the National NeuroAIDS Tissue Consortium (NNTC) gene expression profile dataset. The NNTC dataset consists of samples from 3 different brain regions (white matter, basal ganglia, frontal cortex) of control and HIV-infected patients with or without NCI and HIVE [18]. These brain regions represent myelinated fibers and tracts (white matter), subcortical (basal ganglia) and cortical (frontal cortex) macrodomains, which are affected in neurodegenerative and inflammatory neurological diseases [19–22], including neuroAIDS and HAND [8, 23–27].

For pathway analysis we used the Gene Set Enrichment Analysis (GSEA), a computational method to assess whether a priori defined sets of genes show statistically significant differences between biological states [28]. GSEA was used in conjunction with gene sets from the Molecular Signatures Database (MSigDb), including canonical pathways in the C2 collection [29]. GSEA uses the Kolmogorov-Smirnov statistical test to assess whether a predefined gene set, here a pathway from the C2 collection, is statistically enriched in differentially expressed genes, by testing their distribution in the full list of genes ranked by their differential expression between two biological states [28].

Materials and methods
Dataset and quality assurance (QA)
Clinical and demographic features of the subjects in the NNTC gene expression dataset used for the study are shown in S1 Table. The gene expression dataset consisted of Affymetrix GeneChip® Human Genome U133 Plus 2.0 arrays of the frontal cortex (Brodmann area 9), basal ganglia (head of the caudate nucleus), and white matter (deep frontal lobe). Raw data were downloaded from GEO (GSE35864). We filtered out 9 samples based on quality controls (actin3/actin5 ratio, gapdh3/gapdh5 ratio, NUSE (Normalized Unscaled Standard Errors) and RLE (Relative Log Expression) computed with the packages simpleaffy and affyPLM in R). Normalization was done using GCRMA, with the option fast set to FALSE, which demonstrated similar performance as the MAS5 normalization for reconstructing gene networks, hence for correctly retrieving gene-gene correlation, a key aspect for pathway dysregulation identification [30]. We further checked the expression of markers of neurons (RBFOX3) and oligodendrocytes (MBP) to validate the brain region profiled for white matter and frontal cortex samples, and excluded 2 samples that had conflicting expression according to their classification (D1 WM and D1 FC).

Pathway analysis. For pathway analysis, we selected one representative probe per gene based on the highest observed coefficient of variation of the probes across the samples. The
dataset was interrogated for pathway enrichment using the GSEA algorithm and the canonical pathways from the MSigDb C2 collection (1,237 pathways with at least 10 genes). Here the gene list is ranked according to the statistics of a Welch t-test. For each pathway tested, a running enrichment score is calculated and the maximum enrichment score obtained is associated to the gene set. To test the significance of the enrichment score obtained, it is compared to a null distribution of enrichment scores generated by interrogating the same gene set on randomly generated ranked lists obtained by testing the significance of the genes after shuffling sample labels 1,000 times. Significance was assessed using the False Discovery Rate (FDR) computed as defined in the original GSEA publication for controlling the number of false positives in each GSEA analysis [28]. Differential expression was computed using a Welch t-test from the package Class Comparison in R 3.3.1. We defined the pathways commonly differentially regulated in each comparison as the pathways satisfying an FDR < 0.01 in at least 2 of the 3 brain regions for that comparison while pathways specific to one region were defined as pathways satisfying FDR < 0.01 in that region and FDR > 0.25 in the other 2 regions.

Pathways activity. The activity of a pathway in a sample was computed the following way: we first z-transformed the gene expression profiles to normalize the expression of each gene across samples. We then computed the enrichment score (ES) of a gene set using this z-transformed matrix of expression, as described in the original description of GSEA [28]. The ES corresponds to the relative activity of a gene set in a sample as compared to all others. Hence, the samples with the highest ES are the samples with the highest relative expression of the genes belonging to this set among the samples belonging to the gene expression matrix.

GSEA. Gene set enrichment analysis was implemented in R and follows the method described in [28]. Null distribution was obtained by 1,000 shuffling of the reference list. Gene signatures were obtained by ranking the genes according to the sign of the statistics (S) and the p-value (p) of the test with the following metric: -1 × sign(S) × log(P,10).

Results

Pathway analysis of the NNTC dataset

The NNTC dataset was interrogated for pathway enrichment using the canonical pathways from the MSigDb C2 collection and the GSEA algorithm [28] (See methods). We compared the following four groups: A: controls; B: HIV-infected no NCI no HIVE; C: HIV-infected with NCI no HIVE; D: HIV-infected with NCI and HIVE (Fig 1). All results are presented in supplementary tables in S2–S6 Tables.

Identification of pathways dysregulated in HIV-infected patients without NCI vs. uninfected controls (B-A comparison)

We identified 24 pathways concordantly differentially regulated in at least 2 brain regions in this transition (Table 1). Genes driving the enrichment (on the left of the leading edge corresponding to the peak of the running enrichment in GSEA as shown in Fig 2A) were retrieved for each region (Fig 3). These pathways and genes indicate a significant activation of IFN and cytokine signaling even in the absence of NCI. Both genes regulated by type I and type II IFN were activated in HIV infection without NCI (Figs 2 and 3). IFN-regulated genes, such as MCH class I genes, were induced in all brain regions of HIV-infected patients without NCI as compared to uninfected controls (Figs 2 and 3).

We then looked at pathways specifically differentially regulated in one brain region as compared to the two other regions. To this end, we selected pathways enriched at FDR < 0.01 in one region and FDR > 0.25 in the other two. We observed 6 pathways meeting the criteria in
the white matter, 4 in the frontal cortex and 2 in the basal ganglia. Pathways enriched in the white matter in the B-A comparison are indicative of immune activation, and complement induction (e.g., BIOCARTA COMP PATHWAY, BIOCARTA CTL PATHWAY, REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A
NON LYMPHOID CELL). We also observed increased expression of calpain-related genes (BIOCARTA UCALPAIN PATHWAY) in the frontal cortex and calpain-related and caspases-related genes in the basal ganglia (KEGG APOPTOSIS) as well as evidence of activation of the apoptosis-mediating p75 receptor (PID P75 NTR PATHWAY) and TNF-α signaling (PID TNF PATHWAY) in both frontal cortex and basal ganglia, indicative of tissue damage. Down-regulation of genes related to neurotransmission was also evident in the frontal cortex and basal ganglia of patients with HIV but no NCI (group B) compared to control subjects (e.g., REACTOME LIGAND GATED ION CHANNEL TRANSPORT, KEGG NEUROACTIVE LIGAND RECEPTOR INTERACTION, Fig 4), (S2 Table).

Identification of pathways differentially regulated in HIV-infected patients with NCI without HIVE vs. uninfected controls (C-A comparison)

HIV-infected patients with NCI and no HIVE (group C), showed significant changes specific to the white matter compared to uninfected controls. Upregulated pathways are indicative of immune activation involving chemokine, cytokines and β-defensins induction (e.g.,
Fig 2. Differential regulation of IFN-related pathways in the groups of the NNTC gene expression dataset. A) Gene expression evidence of interferon (IFN) activation in HIV-infected patients without NCI. The diagrams show GSEA plots for 3 pathways representative of IFN activation in HIV-infected patients without NCI (group B, left-hand side in the GSEA plot) as compared to uninfected controls (group A, right-hand side). Each pathway was tested in each region independently. WM = White Matter; FC = Frontal Cortex; BG = Basal Ganglia. These pathways are indicative of type I IFN activation and include IFN-related genes in Top) INTERFERON ALPHA BETA SIGNALING, Middle) type II IFN activation (INTERFERON GAMMA SIGNALING), and Bottom) ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF MHC CLASS I, a pathway involving several IFN-regulated MHC class I genes. Significant changes in the expression of the pathways is indicated by the asymmetric distribution of the genes in the geneset (vertical bars) and of the running enrichment score plot (ES) (19). Genes participating in the enrichment (on the left of the leading edge corresponding to the peak of the running enrichment in GSEA) are shown in Fig 3. B) Differential regulation of IFN-related pathways in the 4 groups of the NNTC gene expression dataset. Significant activation of pathways related to both type I and type II IFN was seen in a brain region-specific pattern in HIV-infected patients without NCI (group B) and in patients with HIV (group D). Top) INTERFERON ALPHA BETA SIGNALING in the white matter, frontal cortex and basal ganglia; Middle) INTERFERON GAMMA SIGNALING; and Bottom) ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF MHC CLASS I, in the same three regions. Each plot represents the pathway activity (computed as an enrichment score) in the 4 different phenotypes and is annotated with the FDR values of respective GSEA comparisons.

https://doi.org/10.1371/journal.pone.0175316.g002

REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES; KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION, REACTOME BETA DEFENSINS, KEGG AUTOIMMUNE THYROID DISEASE, KEGG ALLOGRAFT REJECTION), oxidative stress and cytochrome P450 enzymes (KEGG DRUG METABOLISM CYTOCHROME P450, REACTOME BIOLOGICAL OXIDATIONS), matrix metalloproteases (MMPs) (NABA MATURE SOME ASSOCIATED), and downregulation of genes related to RNA transcription and processing (e.g., REACTOME RNA POL II TRANSCRIPTION, KEGG SPLICEOSOME), (S3 Table), Fig 5.

https://doi.org/10.1371/journal.pone.0175316.g003
Fig 3. Genes differentially expressed in HIV-infected patients without NCI. The heatmap shows the genes in the leading edge of the pathways commonly dysregulated in all 3 brain regions in HIV-infected patients without NCI as compared to uninfected controls. We selected the 54 genes most differentially expressed (t-test, p-value < 0.01) among the list of 128 genes belonging to the leading edges of the significant pathways identified by the GSEA analysis in HIV-infected patients without NCI in comparison with uninfected controls.

https://doi.org/10.1371/journal.pone.0175316.g003
Fig 4. Evidence of neuronal injury in HIV-infected patients without NCI. A) and B) Downregulation of genes related to neuronal transmission in patients with HIV without NCI (group B, left-hand side in the GSEA plot) vs. uninfected controls (Group A). C) Upregulation of apoptotic-related pathways in the frontal cortex and basal ganglia of HIV-infected patients without NCI (group B).

https://doi.org/10.1371/journal.pone.0175316.g004
Identification of pathways differentially regulated between HIV-infected patients with NCI and no HIVE vs. HIV-infected without NCI (C-B comparison)

Two pathways were concordantly differentially regulated between groups B and C in all brain regions. These pathways are indicative of type I IFN activation in HIV-infected patients without NCI (group B), as indicated above. We also identified 47 pathways specifically differentially regulated in the frontal cortex. Among the pathways upregulated in group B as compared to C in the frontal cortex, were pathways indicative of tissue damage (e.g., REACTOME REGULATION OF APOPTOSIS), RNA transcription and processing (e.g., REACTOME METABOLISM OF RNA, KEGG RIBOSOME), and pathways related to protein degradation (e.g., KEGG PROTEASOME, REACTOME AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1, REACTOME APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS), (S4 Table).

Fig 5. White matter changes in HIV-infected patients with NCI without HIVE. GSEA plots representative of induction of cytokines, chemokines and β-defensins in HIV-infected patients with NCI without HIVE (group C in the NNTC gene expression dataset) as compared to uninfected controls.

https://doi.org/10.1371/journal.pone.0175316.g005
Identification of pathways differentially regulated between HIV-infected patients with HIVE vs. patients without NCI (D-B comparison)

Pathways dysregulated in all brain regions in HIVE (group D) as compared to patients with HIV without NCI (group B) are suggestive of disruption of protein folding, a mechanism of neurodegeneration (e.g., REACTOME POST CHAPERONIN TUBULIN FOLDING PATHWAY, REACTOME PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC). Other broadly dysregulated pathways in patients with HIVE (group D) as compared to patients with HIV without NCI (group B) indicate greater and broader activation of inflammatory and immune activation genes in group D as compared to group B. Genes regulated by both type I and type II IFN that were found activated in HIV infection without NCI (group B) as compared to uninfected controls, generally showed greater activation in patients with HIVE (group D). For instance, REACTOME INTERFERON GAMMA SIGNALING was increased in group D in basal ganglia in comparison to group B, and REACTOME INTERFERON ALPHA BETA SIGNALING was increased in group D in both white matter and basal ganglia in comparison to group B. All pathways specifically upregulated in basal ganglia in group D were involved in immune activation (e.g., REACTOME NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION, REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM, KEGG LEISHMANIA INFECTION, PID TCR PATHWAY).

Interestingly, the white matter in group D did not show any specific differentially regulated pathways in comparison to group B; conversely, the frontal cortex had 121 pathways and basal ganglia had 16 pathways significantly activated in group D in comparison to group B. Among the pathways upregulated in the frontal cortex in group D were pathways indicative of production of cytokine, chemokines and β-defensins (e.g., KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION, REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES, REACTOME BETA DEFENSINS). Pathways indicative of neurodegeneration were differentially regulated between groups D and B in the frontal cortex including KEGG PARKINSONS DISEASE and KEGG HUNTINGTONS DISEASE (Fig 6). These pathways include genes indicative of trophic interaction, protein misfolding and mitochondrial function. We also identified downregulated pathways related to mitochondria and energy metabolism were decreased in group D in all brain regions at FDR < 0.2 (e.g., REACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT, REACTOME PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE, REACTOME GLYCOLYSIS), (S5 Table).

Identification of pathways differentially regulated between HIV-infected patients with HIVE vs. patients with NCI and no HIVE (D-C comparison)

We identified 27 pathways concordantly differentially regulated at the C to D comparison. Seventeen pathways were upregulated in group D (HIVE) as compared to group C (NCI without HIV) and largely reflected activation in HIVE of IFN response (e.g., REACTOME INTERFERON SIGNALING, REACTOME INTERFERON GAMMA SIGNALING, KEGG ANTIGEN PROCESSING AND PRESENTATION), immune activation and inflammatory cytokine signaling (e.g., REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM, KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION, REACTOME INNATE IMMUNE SYSTEM), apoptosis (BIOCARTA DEATH PATHWAY), protein misfolding (REACTOME PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC), and HIV infection (PID HIV NEF PATHWAY, REACTOME LATE PHASE OF HIV LIFE CYCLE).

Ten pathways were downregulated in group D and included pathways related to translation and transcription, as seen in the A to B transition, likely reflecting transcriptional/translational dysregulations brought about by IFN activation (e.g., REACTOME TRANSPORT OF
Fig 6. Gene expression evidence of neurodegeneration in the frontal cortex of patients with HIVe. A) Huntington’s disease-related pathways are downregulated in the frontal cortex of patients with HIVe (group D) as compared to HIV-infected patients with NCI and no HIVe as well as with patients without NCI. Similarly, (B) and (C) show Parkinson’s disease and Neuronal System pathways, respectively. Each row represents the pathway activity (computed as an enrichment score) in the 4 different phenotypes and is annotated with the FDR values of respective GSEA comparisons, followed by GSEA plots of the pathways in the group D vs group B and group D vs. group C comparisons in the frontal cortex.

https://doi.org/10.1371/journal.pone.0175316.g006
RIBONUCLEOPROTEINS INTO THE HOST NUCLEUS), HIV expression (REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS, REACTOME LATE PHASE OF HIV LIFE CYCLE), impaired neuronal communication (REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES), and energy metabolism (REACTOME CITRIC ACID CYCLE TCA CYCLE, REACTOME PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE).

Pathways related to neurodegenerative/neuronal pathways were differentially regulated in the frontal cortex and basal ganglia in patients with HIVE, including KEGG HUNTINGTONS DISEASE, KEGG PARKINSONS DISEASE, REACTOME NEURONAL SYSTEM (Fig 6). A significant component of these pathways are genes involved in mitochondria function and energy metabolism. No pathways were specifically different in white matter between groups C and D, while 37 pathways were specific to the frontal cortex and 11 to basal ganglia. Several frontal cortex-specific pathways were downregulated in group D and included cell cycle regulation while basal ganglia pathways were related to translation/transcription and immune regulation (BIOCARTA D4GDI PATHWAY, BIOCARTA 41BB PATHWAY, PID CD8 TCR DOWNSTREAM PATHWAY, PID IL12 STAT4 PATHWAY), (S6 Table).

Discussion

While dementia and HIV encephalitis are late consequences of HIV/AIDS, HIV enters the brain early after infection and remains in the brain throughout the course of infection. A current major challenge is the identification of the pathogenic mechanisms behind HAND, which remain prevalent despite cART [7, 11–15]. To better understand the pathogenetic processes behind HIV-associated neurological complications, here we employed the GSEA computational method for pathway analysis in conjunction with the MSigDb pathway collection [28, 29]. This approach is particularly suited for this analysis as it allows for a non-biased interrogation of the data by inputting all genes from transcriptional profiling results without a priori selecting individual genes based on their differential expression. In this way, all genes in the experiment contribute to the statistical analysis allowing to interrogate the whole transcriptional landscape in a systems biology framework. Additionally, as GSEA interrogates differential expression within genesets, it is more sensitive than traditional threshold-based analysis where cutoffs can have a dramatic impact on gene selection. The brain regions profiled included white matter (representative of myelinated fibers and tracts); basal ganglia (subcortical region) and frontal cortex (cortical region) that are affected in neurodegenerative and inflammatory brain disease and HAND [23–27].

A considerable body of observations indicate that neuroinflammatory markers correlate with disease progression and the emergence of NCI in neuroAIDS [31–33]. Proinflammatory cytokines and chemokines including IFN-α, TNF-α and CCL2 that are secreted by astrocytes and microglia have long been implicated in the pathogenesis of neuroAIDS [34–38]. For instance, IFN-α in the cerebrospinal fluid has been observed to be higher in HAD compared with HIV-infected patients without HAD [34, 37, 39]. Here, we show that HIV infection is associated with substantial dysregulations of gene expression related to immune activation in the absence of NCI. This observation suggests that considerable immune activation and neuroinflammation can precede the onset of NCI and/or occur in individuals resistant to progression to clinical NCI.

In particular, a primary finding in the present study is that gene expression evidence of the induction of both IFN type I and type II responsive genes was seen in patients with HIV infection without NCI (group B) in all brain regions studied as well as in patients with HIVE (group D). Among the genes differentially regulated within these pathways were IFN-
responsive genes such as HLA-A, -B, -C, -G, -F, adhesion molecules such as VCAM-1, and ISG15 and IFI6 [40–42].

Chronic IFN expression is considered a key contributor to inflammation in neuroAIDS as well as a potential cause of NCI and depression vulnerability. However, data on the contribution of IFN activation to NCI are conflicting. Mice with transgene expression of IFN-α in astrocytes develop a dose-dependent inflammatory encephalopathy [43]. Yet IFN-α transgenic expression in the central nervous system induced only mild effects in an egocentric spatial working memory test [44]. However, the latter may also reflect compensatory changes as passively administered IFN-β impaired spatial memory in mice in another study [45]. A recent study suggested a role for IFN-γ in shaping fronto-cortical connections and social behavior [46], which is consistent with a potential role of excessive IFN activation in the pathogenesis of NCI. In a recent large multi-center trial, depression was not significantly increased by IFN-β treatment for multiple sclerosis (MS) [47]. The induction of IFN in patients of the NNTC data set without NCI (group B) is reminiscent of previous studies in which IFN induction was not closely correlated with NCI, e.g., [48], and raises the possibilities that either protracted IFN dysregulation may be required to produce NCI or that it may be a co-factor in NCI pathogenesis.

Also evident in HIV-infected patients without NCI was the activation of mechanisms indicative of tissue injury, such as expression of matrix metalloproteases (MMP) and complement-related genes in the white matter. MMP expression by HIV-1 infected monocytes and macrophages is recognized as a pathogenic mechanism in neuroAIDS [49]. Elevated MMP levels can contribute to microglial activation, infiltrate through cleavage of adhesion molecules, neuronal and synaptic injury, as well as blood-brain barrier disruption [50–53]. MMP increases were present in the white matter in HIV-infected patients with NCI and no HIVE, while in patients with HIVE, induction of MMPs was also evident both in the white matter and in the frontal cortex.

Another key finding in the study is that patients with NCI without HIVE (group C) in the NNTC cohort did not show significant activation of IFN, unlike patients in groups B and D. This discordant regulation of IFN signaling did not appear to be associated with antiretroviral therapy as patients with NCI and no HIVE include both patients treated with antiretrovirals and untreated patients. Conversely, patients with NCI without HIVE (group C) had increased expression of chemokines, cytokines and β-defensins in the white matter. Other proinflammatory markers were also concomitantly increased in the white matter of patients with NCI and no HIVE. Evidence of chemokine and cytokine expression were present in all HIV-infected groups in the study, β-defensins were also induced in patients with HIVE.

Chemokines have been implicated in impairing cognition, Alzheimer’s disease and depression as well as other psychiatric conditions [54]. Increased immunoreactivity for MCP-2 was noted in MS lesions [55]. A chemokine gene cluster has been associated with age of onset of Alzheimer’s [56]. A higher level of CCL2 in CSF, and a CCL2 -2578G allele, have been associated with worse neurocognitive functioning in HIV [57]. Animal studies, while scant, are consistent with a possible role for chemokines in NCI. For instance, chemokine signaling was increased by SIV infection and methamphetamine exposure in macaques [58, 59]. Chemokines can induce changes leading to impaired hippocampal synaptic transmission, plasticity and memory [59, 60]. Evidence also suggests a role for defensins in the chronic inflammation associated with degenerative brain diseases, and in particular Alzheimer’s disease [61, 62]. Defensins-related pathways were also induced in HIVE, but showed no consistent regulation in HIV-infected patients without NCI, suggesting a possible contribution to the pathogenesis of NCI.

In HIV without NCI, genes related to neurotransmission were also downregulated in the frontal cortex and basal ganglia while genes related to apoptosis, such as calpain-related
mechanisms, which contribute to neurodegeneration in HIV [63], were induced in the basal ganglia and frontal cortex. Conversely, no pathways showed significant dysregulations in the frontal cortex and basal ganglia in HIV patients with NCI and no HIVE. In HIVE, multiple pathways indicative of impaired mitochondria and energy metabolism were differentially regulated. In NCI without HIVE, we observed increased expression of cytochrome P450 enzymes, which may indicate oxidative stress [64].

The anatomical distribution of the gene expression programs dysregulated in the NNTC dataset appears to reflect brain-region specific dynamics in neurological disease progression in HIV/AIDS. In particular, we observed some degree of white matter alteration of gene expression in all HIV-infected groups with and without NCI and HIVE. However, gene expression changes in patients with NCI without HIVE (group C) were localized to the white matter and had a specific gene expression profile. Lack of gene expression changes suggestive of neuronal injury in the frontal cortex and basal ganglia in patients with NCI without HIVE (group C) suggests that they may not be accompanied by significant neuronal atrophy, but that white matter pathology likely drives NCI in these patients. Prominent white matter gene expression changes were also present in HIVE, which was also characterized by considerable gene expression changes in the frontal cortex and basal ganglia, consistent with earlier clinical literature, e.g. [8]. White matter damage correlating with the severity of cognitive manifestations has been observed since the early days of the HIV pandemic [8, 25]. Evidence of white matter injury in HIV-infected patients with and without NCI is also demonstrated in recent imaging studies [65, 66]. Importantly, white matter changes are increasingly recognized as predictive of cognitive impairment and progression to dementia in aging and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease [19–22]. In addition to white matter changes, gene expression in HIVE was characterized by considerable changes in the frontal cortex and basal ganglia, which is in agreement with the association of NCI with progression of functional abnormalities involving the basal ganglia and the frontal cortex [23–27].

The present study has several limitations. Primarily, the NNTC dataset groups are of small sample size that was further reduced as part of the quality control analysis. Larger studies will be needed to better understand the pathogenesis and progression of neurological disease and to adequately represent all possible variants of central nervous system disease. For instance, gene expression results of the group of HIV-infected patients with NCI and without HIVE raise several questions, including if this is a distinct nosologic variant of neuroAIDS or if it is a stage in the progression of HIV brain disease.

In conclusion, in the present study we explored patterns of gene expression dysregulation in patients in the NNTC neuroAIDS gene expression dataset. Results point to gene expression changes indicative of immune activation characterized by IFN and cytokine expression as well as evidence of neuronal injury preceding NCI. Interestingly, the group of HIV-infected patients with NCI without HIVE showed a preeminently white matter dysfunction characterized by a distinct pattern of immune activation with low IFN. Larger studies are necessary to better understand the pathogenesis of neurological disease and its progression, to evaluate the impact of therapy on various HIV disease conditions, and to identify better therapeutic targets and strategies for NCI in HIV.

Supporting information

S1 Table. Clinical and demographic features of the subjects selected in the study.
(XLSX)

S2 Table. Pathways enriched in the A-B comparison.
(XLSX)
S3 Table. Pathways enriched in the A-C comparison.
(XLSX)

S4 Table. Pathways enriched in the B-C comparison.
(XLSX)

S5 Table. Pathways enriched in the B-D comparison.
(XLSX)

S6 Table. Pathways enriched in the C-D comparison.
(XLSX)

Acknowledgments
This is manuscript #29423 from The Scripps Research Institute.

Author Contributions

Conceptualization: PPS CL.

Data curation: CL.

Formal analysis: PPS VRC EM CL.

Funding acquisition: PPS EM.

Project administration: PPS.

Writing – original draft: PPS VRC EM CL.

Writing – review & editing: PPS VRC EM CL.

References

1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of neurovirology. 2011; 17(1):3–16. Epub 2010/12/22. https://doi.org/10.1007/s13365-010-0006-1 PMID: 21174240

2. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. Journal of neurovirology. 2004; 10(6):350–7. https://doi.org/10.1080/13550280490521078 PMID: 15765806

3. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005; 21(8):706–13. https://doi.org/10.1089/aid.2005.21.706 PMID: 16131310

4. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31(2):171–7. PMID: 12394795

5. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004; 157(1–2):3–10. https://doi.org/10.1016/j.jneuroim.2004.08.042 PMID: 15579274

6. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. Aids. 2004; 18 Suppl 1:S75–8.

7. Everall IP, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of neurovirology. 2009;1–11. Epub 2009/09/10.

8. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res. 2005; 8(1–2):51–61. PMID: 16260385
Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al. Cortical synaptic denervation is reduced in patients despite long-standing suppression of viremia. Aids. 2010; 24(9):1243–50. https://doi.org/10.1097/QAD.0b013e3283354a7b PMID: 20660506

9. Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. Journal of leukocyte biology. 2003; 74(5):691–701. Epub 2003/11/05. https://doi.org/10.1189/jlb.0503205 PMID: 14595004

10. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993; 43(11):2245–52. PMID: 8232937

11. Ellis R, Langford D, Maslia E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007; 8(3):33–44. https://doi.org/10.1038/nrn2040 PMID: 17180161

12. Maslia E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Annals of neurology. 1997; 42(6):963–72. https://doi.org/10.1002/ana.410420618 PMID: 9403489

13. McPhail ME, Robertson KR. Neurocognitive impact of antiretroviral treatment: thinking long-term. Current HIV/AIDS reports. 2011; 8(4):249–56. https://doi.org/10.1007/s11904-011-0091-7 PMID: 21837444

14. Simioni S, Cavassini M, Annino JM, Rimbaud Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids. 2010; 24(9):1243–50. https://doi.org/10.1097/QAD.0b013e3283354a7b PMID: 19996937

15. Desplats P, Dumaop W, Smith D, Adame A, Everall I, Letendre S, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013; 80(15):1415–23. https://doi.org/10.1212/WNL.0b013e318283354a PMID: 23486877

16. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron. 2009; 64(1):133–45. Epub 2009/10/21. https://doi.org/10.1016/j.neuron.2009.09.042 PMID: 19840555

17. Levine AJ, Soontornniyomkij V, Achim CL, Maslia E, Gelman BB, Simsheimer JS, et al. Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV. Journal of neurovirology. 2016; 22(4):431–41. https://doi.org/10.1007/s13365-015-0410-7 PMID: 26637429

18. Gelman BB, Chen T, Linsinichia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National NeuAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PloS one. 2012; 7(9):e46178. Epub 2012/10/11. https://doi. org/10.1371/journal.pone.0046178 PMID: 23049970

19. Brickman AM, Honig LS, Scarmneas N, Tatarina O, Sanders L, Albert MS, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008; 65(9):1202–8. https://doi.org/10.1001/archneur.65.9.1202 PMID: 18779424

20. Debetto S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010; 341:c3666. https://doi.org/10.1136/bmj.c3666 PMID: 20660506

21. Kandiah N, Mak E, Huang S, Au WL, Sitoh YY, et al. Cerebral white matter hyperintensity in Parkinson’s disease: a major risk factor for mild cognitive impairment. Parkinsonism Relat Disord. 2013; 19(7):680–3. https://doi.org/10.1016/j.pard.2013.03.008 PMID: 23623194

22. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013; 70(4):455–61. https://doi.org/10.1001/jamaneurol.2013.1321 PMID: 23420027

23. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JS, et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Annals of neurology. 1997; 42(6):963–72. https:/ /doi.org/10.1002/ana.410420618 PMID: 9403489

24. Ipser JC, Brown GG, Bischoff-Grethe A, Connolly CG, Ellis RJ, Heaton RK, et al. HIV infection is associated with attenuated frontostriatal intrinsic connectivity: a preliminary study. J Int Neuropsychol Soc. 2015; 21(3):203–13. https://doi.org/10.1017/S1355617715000156 PMID: 25824201

25. Aylward EH, Brett Schneider PD, McArthur JC, Harris GJ, Schlaper FF, Henderer JD, et al. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry. 1995; 152(7):987–94. https://doi.org/10.1176/ajp.152.7.987 PMID: 7793469

26. Steinbrink F, Evens S, Buerke B, Young P, Arendt G, Koutsiliery E, et al. Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol. 2013; 20(3):420–8. https://doi.org/10.1111/ejn.12006 PMID: 23095123

27. Kuper M, Rabe K, Esser S, Gisewski ER, Husstedt IW, Maschke M, et al. Structural gray and white matter changes in patients with HIV. J Neurol. 2011; 258(6):1066–75. https://doi.org/10.1007/s00415-010-5833-y PMID: 21207051

28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings
of the National Academy of Sciences of the United States of America. 2005; 102(43):15545–50. Epub 2005/10/04. https://doi.org/10.1073/pnas.0506580102 PMID: 16199517

29. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1(6):417–25. https://doi.org/10.1016/j.cels.2015.12.004 PMID: 26771021

30. Lim WK, Wang K, Lefebvre C, Califano A. Comparative analysis of microarray normalization procedures: effects on reverse engineering gene networks. Bioinformatics. 2007; 23(13):i282–8. Epub 2007/07/25. https://doi.org/10.1093/bioinformatics/btm201 PMID: 17646307

31. Schrier RD, Hong S, Crescini M, Ellis R, Perez-Santiago J, Spina C, et al. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). PloS one. 2015; 10(2):e0116526. https://doi.org/10.1371/journal.pone.0116526 PMID: 25719800

32. Gelman BB, Lisinicchia JG, Morgello S, Masliah E, Commins D, Achim CL, et al. Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr. 2013; 62(5):487–95. https://doi.org/10.1097/QAI.0b013e31827f1bcb PMID: 23242157

33. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008; 29(8):357–65. https://doi.org/10.1016/j.it.2008.05.002 PMID: 18599350

34. Rho MB, Wesselingh S, Glass JD, McArthur JC, Choi S, Griffin J, et al. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain, behavior, and immunity. 1995; 9(4):366–77. https://doi.org/10.1016/brbi.1995.1034 PMID: 8903853

35. Zheng J, Thylin MR, Persidsky Y, Williams CE, Cotter RL, Zink W, et al. HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotox Res. 2001; 3(5):461–84. PMID: 14715459

36. Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Annals of neurology. 1992; 31(4):349–60. https://doi.org/10.1002/ana.410310402 PMID: 1586135

37. Perrella O, Carreiri PB, Perrella A, Sbreglia C, Gorga F, Guarnaccia D, et al. Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load? Eur Cytokine Netw. 2001; 12(1):51–5. PMID: 11282546

38. Ryan LA, Cotter RL, Zink WE 2nd, Gendelman HE, Zheng J. Macrophages, chemokines and neuronal injury in HIV-1-associated dementia. Cell Mol Biol (Noisy-le-grand). 2002; 48(2):137–50.

39. Krivine A, Force G, Servan J, Cabee A, Rozenberg F, Dighiero G, et al. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. Journal of neurovirology. 1999; 5(5):500–6. PMID: 18599350

40. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997; 15:749–95. https://doi.org/10.1146/annurev.immunol.15.1.749 PMID: 9143706

41. Burrone OR, Milstein C. Control of HLA-A,B,C synthesis and expression in interferon-treated cells. EMBO J. 1982; 1(3):345–9. PMID: 6765173

42. Calabresi PA, Tranquilli LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Annals of neurology. 1997; 41(5):669–74. https://doi.org/10.1002/ana.410410517 PMID: 9153530

43. Hofer MJ, Campbell IL. Type I interferon in neurological disease-the devil from within. Cytokine Growth Factor Rev. 2013; 24(3):257–67. https://doi.org/10.1016/j.cytogfr.2013.03.006 PMID: 23548179

44. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain research. 2001; 902(1):46–61. Epub 1999/08/17. PMID: 10448195

45. Blank T, Detje CN, Spiess A, Hagemeyer N, Brendecke SM, Wolfart J, et al. Brain Endothelial-Specific Interferon Receptor Chain 1 Drives Virus-Induced Sickness Behavior and Cognitive Impairment. Immunity. 2016; 44(4):901–12. https://doi.org/10.1016/j.immuni.2016.04.005 PMID: 27096319

46. Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, et al. Unexpected role of interferon-gamma in regulating neuronal connectivity and social behaviour. Nature. 2016.

47. Schippling S, O’Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016; 263(7):1418–26. https://doi.org/10.1007/s00415-016-8146-8 PMID: 27177997

48. Shapshak P, Duncan R, Minagar A, Rodriguez de la Vega P, Stewart RV, Goodkin K. Elevated expression of IFN-gamma in the HIV-1 infected brain. Front Biosci. 2004; 9:1073–81. PMID: 14977530
49. Webster NL, Crowe SM. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. Journal of leukocyte biology. 2006; 80(5):1052–66. https://doi.org/10.1189/jlb.0306152 PMID: 16959898

50. Conant K, Lim ST, Randall B, Maguire-Zeiss KA. Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine. Current HIV research. 2012; 10(5):384–91. PMID: 22591362

51. Dziembowska M, Włodarczyk J. MMP9: a novel function in synaptic plasticity. Int J Biochem Cell Biol. 2012; 44(5):709–13. https://doi.org/10.1016/j.biocel.2012.01.023 PMID: 22326910

52. Nottet HS. Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood—brain barrier function. Journal of neurovirology. 1999; 5(6):659–69. PMID: 10602406

53. Louboutin JP, Strayer DS. Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications. ScientificWorldJournal. 2012; 2012:482575. https://doi.org/10.1100/2012/482575 PMID: 22448134

54. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neuroscience and biobehavioral reviews. 2014; 42:93–115. https://doi.org/10.1016/j.neubiorev.2014.02.001 PMID: 24513303

55. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol. 1998; 86(1):20–9. PMID: 9655469

56. Lalli MA, Bettcher BM, Arcila ML, Garcia G, Guzman C, Madrigal L, et al. Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer’s disease. Mol Psychiatry. 2015; 20(11):1294–300. https://doi.org/10.1038/mp.2015.131 PMID: 26324103

57. Thames AD, Briones MS, Maguantay LI, Martinez-Maza O, Singer EJ, Hinkin CH, et al. The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. Aids. 2015; 29(12):1483–91. https://doi.org/10.1097/QAD.0000000000000706 PMID: 26244388

58. Najera JA, Bustamante EA, Bortell N, Morsey B, Fox HS, Ravasi T, et al. Methamphetamine abuse affects gene expression in brain-derived microglia of SIV-infected macaques to enhance inflammation and promote virus targets. BMC Immunol. 2016; 17(1):7. https://doi.org/10.1186/s12865-016-0145-0 PMID: 27107567

59. Gersten M, Alirezaei M, Marcondes MC, Flynn C, Ravasi T, Ideker T, et al. An integrated systems analysis implicates EGR1 downregulation in simian immunodeficiency virus encephalitis-induced neural dysfunction. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(40):12467–76.

60. Marciniak E, Faivre E, Dutar P, Alves Pires C, Demeyer D, Caillierez R, et al. The Chemokine MIP-1alpha/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep. 2015; 5:15862. https://doi.org/10.1038/srep15862 PMID: 26511387

61. Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, et al. Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113(16):4350–5. https://doi.org/10.1073/pnas.1601831113 PMID: 27044108

62. Williams WM, Torres S, Siedlak SL, Castellani RJ, Perry G, Smith MA, et al. Antimicrobial peptide beta-defensin-1 expression is upregulated in Alzheimer’s brain. J Neuroinflammation. 2013; 10:127. https://doi.org/10.1186/1742-2094-10-127 PMID: 24139179

63. Zyskind JW, Wang Y, Cho G, Ting JH, Kolson DL, Lynch DR, et al. E2F1 in neurons is cleaved by calpain in an NMDA receptor-dependent manner in a model of HIV-induced neurotoxicity. Journal of neurochemistry. 2015; 132(6):742–55. https://doi.org/10.1111/jnc.12956 PMID: 25279448

64. Ande A, Sinha N, Rao PS, McArthur CP, Ayuk L, Achu PN, et al. Enhanced oxidative stress by alcohol use in HIV+ patients: possible involvement of cytochrome P450 2E1 and antioxidant enzymes. AIDS Res Ther. 2015; 12:29. https://doi.org/10.1186/s12981-015-0071-x PMID: 26396584

65. Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, et al. White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. Journal of neurovirology. 2009; 15(2):187–95. https://doi.org/10.1080/13550280902769756 PMID: 19306228

66. Stubbe-Drger B, Deppe M, Mohammadi S, Keller SS, Kugel H, Gregor N, et al. Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol. 2012; 12:23. https://doi.org/10.1186/1471-2377-12-23 PMID: 22548835